Reaction

Peripheral Motor Neuropathy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,378 reports · 71 co-occurring drugs

As of the last recalculation, Peripheral Motor Neuropathy appears in 1,378 FAERS reports alongside 71 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 95.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Brentuximab Vedotin	62	95.6	96.2
Mesna Injection	17	31.5	31.5
Mesna	17	30.9	30.9
Vincristine Sulfate	46	24.5	24.5
Pegaspargase	19	23.8	23.8
Doxorubicin Hydrochloride	47	22.5	22.5
Bleomycin Sulfate	15	22.2	22.2
Doxorubicin	115	21.2	21.2
Cytarabine	78	20.7	20.8
Mercaptopurine	22	19.5	19.5
Nebivolol	20	19.2	19.3
Bortezomib	105	19.1	19.1
Etoposide	87	19.0	19.0
Filgrastim	43	17.8	17.8
Paclitaxel	108	17.8	17.8
Bendamustine Hcl	17	16.8	16.8
Cyclophosphamide Injection, Solution	173	16.7	16.8
Cyclophosphamide	173	16.7	16.8
Cyclophosphamide For Injection	173	16.7	16.8
Oxaliplatin	77	16.5	16.6
Polatuzumab Vedotin	10	15.6	15.6
Paclitaxel (Aibumin-Bound)	80	15.5	15.6
Vemurafenib	12	15.2	15.2
Granisetron Hydrochloride	10	14.6	14.6
Thalidomide	34	14.3	14.3
Atazanavir	13	13.8	13.8
Ifosfamide	19	13.5	13.5
Ipilimumab	37	13.3	13.3
Atezolizumab	33	13.1	13.1
Blinatumomab	9	13.1	13.1
Granisetron	9	13.0	13.0
Leucovorin Calcium	15	12.0	12.0
Irinotecan Hydrochloride	10	11.8	11.8
Panitumumab	12	11.7	11.7
Dexamethasone 1.5 Mg	187	11.0	11.0
Dexamethasone	187	10.9	10.9
Bevacizumab	83	10.7	10.7
Carboplatin	85	10.7	10.7
Fluorouracil Cream, 0.5%	51	10.4	10.5
Loperamide Hydrochloride Oral	7	10.4	10.4
Fluorouracil	51	10.3	10.3
Cetuximab	21	10.3	10.3
Trastuzumab	45	10.2	10.2
Temozolomide	14	10.1	10.1
Capecitabine	59	10.1	10.1
Gemcitabine	25	9.7	9.7
Nebivolol Hydrochloride	21	9.5	9.5
Dabrafenib	13	9.4	9.4
Encorafenib	6	9.2	9.2
Amikacin	10	8.9	8.9
Fosaprepitant Dimeglumine	8	8.8	8.8
Linezolid	17	8.7	8.7
Gemcitabine Hydrochloride	30	8.7	8.7
Pertuzumab	15	8.4	8.4
Cisplatin	40	7.9	7.9
Lapatinib	8	7.8	7.8
Ado-Trastuzumab Emtansine	4	7.2	7.2
Trametinib	11	6.9	6.9
Nivolumab	43	6.9	6.9
Docetaxel Anhydrous	28	6.4	6.4
Docetaxel	28	6.4	6.4
Pemetrexed	9	6.4	6.4
Bendamustine Hydrochloride	5	6.3	6.3
Erlotinib	4	6.3	6.3
Erlotinib Hydrochloride	5	6.1	6.1
Pemetrexed Disodium	15	6.0	6.0
Emtricitabine And Tenofovir Disoproxil Fumarate	17	5.7	5.7
Pembrolizumab	37	5.4	5.4
Daratumumab	14	5.3	5.3
Pegfilgrastim	22	3.4	3.4
Pomalidomide	21	3.1	3.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.